Inspire Medical Systems, Inc. (INSP): what the price assumes

In the published model solve dated 2026-Q2, anchored at $51.82, Inspire Medical Systems, Inc. (INSP) is priced for today's economics sustained for ~30.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/INSP

Headline

FieldValue
TickerINSP
CompanyInspire Medical Systems, Inc.
Current price$51.82/sh
CompositionUnited States 96% / All other countries 4%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Must persist for30.2y
Multiple paid384x operating income

Solve inputs: computed at a 10.9% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.5 years.

Reconcile: at the x-ray's 9.3% required return this reads ~25 years; the models below use their own rates.

How unusual the bet is: elevated (limited comparison data)

ReferenceValue
sustained it ~10 years at this level14%
implied end-window share1%

Valuation X-Ray

The price is supported by asset-based and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.89x4justifies
Earnings1.37x3expensive
Relative0.78x3justifies
Growth0.81x3justifies

Families that justify the price: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$83.610.62xyesFCF base $0.1B, growth 9% (input: historical growth), terminal g 4.0%, WACC 9.0%, 6yr projection
DCF Exit MultipleGrowth$63.630.81xyesExit EV/EBITDA: 19.5x / 21.5x / 23.5x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$66.540.78xyesP/E 18.94x (blended: static sector reference 24x + trailing (TTM) 11x), scenarios: 15.8x / 18.9x / 22.1x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$49.401.05xyesBV/sh $27.61, ROE (TTM) 16.6%, ke 9.3%
Two-Stage Excess ReturnAsset$65.220.79xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$44.141.17xyesRev $0.9B, growth 9% (input: historical growth; tapered), Terminal P/S: 1.4x / 1.6x / 1.9x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset$65.930.79xyesBV $27.61 + 5yr PV of (ROE (TTM) 16.6% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$52.280.99xyes√(22.5 × EPS $4.40 × BVPS $27.61) — Graham's conservative floor
EV/EBITDA RelativeRelative$38.951.33xyesEBITDA $0.07B × sector EV/EBITDA 16.0x
FCF YieldEarnings$37.811.37xyesFCF $96.7M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$3.6914.04xyesEPS $4.40 × (8.5 + 2×-5.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$127.560.41xyesRevenue $0.92B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$47.571.09xyesEPS $4.40 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$283.8m
Net debt / NOPAT (after-tax)-96.45x (net cash)
Net debt / operating income (pre-tax)-76.20x (net cash)
Share count CAGR (dilution)1.1%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Start with the bear's case, because it explains why the stock is where it is: investors worry that weight-loss drugs will shrink the sleep-apnea population, that reimbursement changes will discourage doctors from implanting the device, and that growth has already slowed sharply. Those are real concerns, and the stock has fallen hard on them. The question is whether the data supports the alarm, and on the most important measure it does not: Inspire is still growing, treated more than 125,000 patients cumulatively, and generated $912 million of revenue in 2025, up 14%. A company the market is pricing as if it is in decline is in fact still expanding its patient base and its revenue.

The product itself is the durable asset. Inspire's therapy is an implanted device that stimulates the airway nerve during sleep, a one-time procedure that frees patients from the CPAP mask many cannot tolerate. That clinical differentiation has built a genuine franchise, and the company is reinvesting in it: the launch of the next-generation Inspire V system is progressing, with early commercial adoption validating the patient outcomes and improving therapy delivery. A newer, better device defends the position against competitors and gives the salesforce a fresh reason to engage physicians, which is how a medical-device company sustains adoption.

The valuation has reset to where the methods now read the stock as inexpensive. After the price decline, the asset-based, growth, and relative-multiple methods all land at or above the current price, marking Inspire as supported rather than stretched, a notable shift for a former high-flyer. The balance sheet reinforces the durability: about $284 million of net cash, no debt, and a near-break-even-to-profitable operating model with 2026 adjusted earnings per share guided to $1.85 to $2.35.

Bear Case

The structural truth a holder has to confront is that two forces outside the company's control are pressing on the demand for its device at the same time. The first is reimbursement. Inspire's revenue depends on physicians being paid adequately to implant the device, and the transition to a new procedure code with a modifier could reduce the professional fee by 10% to 50%. A cut of that size goes straight to the surgeon's incentive to perform the procedure, and a device company cannot grow faster than doctors are willing to implant its product. On top of that, a Medicare prior-authorization pilot in six states has already caused disruptions and denials, hitting Medicare procedures. Reimbursement is the plumbing of a medical-device business, and when it tightens, volume follows.

The second force is the harder one to dismiss: weight-loss drugs. Obstructive sleep apnea is strongly linked to obesity, and the GLP-1 drugs that are driving large, sustained weight loss across millions of patients directly target the underlying condition that creates much of Inspire's market. If a meaningful share of moderate sleep-apnea patients lose enough weight to no longer need a surgical implant, the addressable population shrinks. This is not a near-term revenue line item; it is a long-term question mark hanging over the entire thesis, and it is exactly the kind of structural overhang that justifies a lower multiple even on a growing company.

The deceleration is the evidence those forces are already biting. Revenue growth slowed from 14% in 2025 to a guided 4% to 10% for 2026, and the company explicitly noted its outlook includes no contribution from improved reimbursement, meaning the guidance already bakes in the headwinds rather than hoping they resolve. The balance sheet is genuinely strong, net cash and no debt, so this is emphatically not a solvency bear; Inspire has the resources to weather a slow patch and fund the Inspire V rollout. The bear case is about the trajectory: a company whose growth is decelerating into a reimbursement squeeze and a structural GLP-1 overhang may deserve a modest multiple precisely because the path from here is narrower than the patient-base story suggests.

Valuation

The whole-company operating-income multiple looks alarming at first glance and is misleading on its own. Because Inspire runs near break-even on a GAAP operating basis, with an operating margin around 5.6%, dividing the price by that razor-thin operating profit produces an enormous multiple. That is an artifact of a company still scaling its profitability, not a meaningful read of value, and it would wrongly imply the price requires decades of ceiling growth. The methods that look at the business through revenue, assets, and growth tell a different and more useful story.

Those methods, taken together, read the price as supported. After the stock's steep decline, the asset-based, growth, and relative-multiple families all land at or above the current price, and only one earnings-based lens reads it as slightly rich. That is the signature of a former premium-growth name that has de-rated to the point where the value methods catch up to it: the price fell faster than the fundamentals, and the spread between them closed. The cleanest interpretation is that the market repriced Inspire for the reimbursement and GLP-1 risks, and at $42.64 (June 27, 2026) the cushion that a 14%-growing, debt-free, profitable medical-device franchise should carry has largely returned. Against its medical-device peer cohort, the multiple is no longer the outlier it once was.

Solvency is a clear strength and bounds the downside firmly. Inspire holds about $284 million of net cash, carries no debt, and is profitable on an adjusted basis, with 2026 adjusted earnings per share guided to $1.85 to $2.35. There is no scenario in these numbers where the balance sheet forces a capital raise or a retrenchment; the company can fund the Inspire V launch and ride out a reimbursement disruption from its own resources. What bounds the downside is therefore the cash plus the value of a still-growing therapy, not any financial fragility. The buyer at this price is paying a reset multiple for a profitable, cash-rich device maker whose growth has slowed, accepting the reimbursement and weight-loss-drug risks in exchange for a valuation the methods now call fair.

Catalysts

The full-year 2025 results showed growth slowing from a high base. Revenue reached $912 million, up 14% year over year, and cumulative patients treated surpassed 125,000. The 2026 guidance is the more important signal: revenue of $950 million to $1 billion, implying 4% to 10% growth, with an adjusted operating margin of 6% to 8% and adjusted earnings per share of $1.85 to $2.35. The sharp step-down in the growth rate is the number that has reset expectations.

The live catalysts are mostly reimbursement and product. The transition to a new procedure code with a modifier could cut the professional fee by 10% to 50%, and a Medicare prior-authorization pilot in six states has caused denials and disruption, with management noting its outlook assumes no benefit from improved reimbursement. On the product side, the Inspire V launch is progressing, with early adoption validating patient outcomes. The events to watch are any resolution of the coding and prior-authorization issues, which could lift the guidance the company has deliberately kept conservative, the pace of Inspire V adoption, and any data on whether weight-loss drugs are measurably affecting the sleep-apnea procedure pipeline, because that is the long-term swing factor for the entire market.

Peer Cohorts (Per Segment, With Filing Citations)

Inspire Medical Systems (single segment) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Inspire FY2025 results, 8-K · Inspire 2026 guidance · Inspire 2025 commentary

View the full interactive INSP report on boothcheck